Compare CHMG & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CHMG | LRMR |
|---|---|---|
| Founded | 1833 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 398.6M | 455.8M |
| IPO Year | 1995 | 2014 |
| Metric | CHMG | LRMR |
|---|---|---|
| Price | $80.49 | $1.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $89.30 | $14.40 |
| AVG Volume (30 Days) | 53.7K | ★ 1.5M |
| Earning Date | 10-27-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.73 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.63 | N/A |
| Revenue Next Year | $7.77 | N/A |
| P/E Ratio | $21.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $50.05 | $1.95 |
| 52 Week High | $86.00 | $6.42 |
| Indicator | CHMG | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 43.65 | 16.14 |
| Support Level | $79.75 | N/A |
| Resistance Level | $84.69 | $3.76 |
| Average True Range (ATR) | 1.85 | 0.16 |
| MACD | -0.21 | -0.08 |
| Stochastic Oscillator | 41.12 | 8.46 |
Chemung Financial Corp is a bank holding firm. Through its subsidiaries, the company provides various financial services, including demand, savings, and time deposits, commercial, residential, and consumer loans, letters of credit, wealth management services, employee benefit plans, insurance products, mutual funds, and brokerage services, among others. The company's reportable segments are Core Banking, Wealth Management (WMG) services, and Holding company and CFS. Maximum revenue is generated from the Core Banking segment, which derives revenue by attracting deposits from the general public and using such funds to originate different types of loans, and to invest in securities. The Wealth Management (WMG) services segment provides trust and investment advisory services to clients.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.